Skip to content
PeptideFactSheets

Oxidation-reduction drug and dye · Fact sheet

Methylene blue

Also known as Methylthioninium chloride · ProvayBlue

Methylene blue has an FDA-approved product for acquired methemoglobinemia, a blood oxygen-transport disorder. Small cognitive studies do not establish a general nootropic or anti-aging benefit, and serious drug interactions are a central concern.

FDA approved for specific usesEarly human evidence
Specific conditionsBrain, mood & sleepAging & energy

What is Methylene blue?

Methylene blue is a redox-active small molecule and dye. Evidence for a regulated medical product cannot be transferred to technical dyes or unverified wellness preparations.

Benefits people look for

Mental clarity, memory, energy, and mitochondrial support drive interest. These claims concern different populations and outcomes from the approved blood-disorder indication.

What the evidence supports

  • ProvayBlue treats acquired methemoglobinemia in its labeled medical setting.
  • Small experiments found selected memory effects, but no dependable evidence of everyday cognitive enhancement or longer life.
All research areas
  • Acquired methemoglobinemia
  • Memory tasks
  • Fear-extinction learning

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.

We do not fill this gap with unsourced testimonials or estimated success rates.

Side effects & risks

  • The label has a boxed warning about serious or fatal serotonin syndrome with serotonergic medicines and opioids.
  • G6PD deficiency is a contraindication because of hemolysis risk; severe allergy is also a concern.
  • Discoloration, headache, nausea, and altered taste are among reported effects. Pregnancy and lactation carry specific label precautions.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Early human evidence

The cognitive evidence includes a 26-person healthy-adult imaging study and a 42-person fear-learning study. Both are small and context-specific; this grade describes the frontier claims, not denial of the approved medical use.

Selected research to read

FDA approval & research status

ProvayBlue is FDA approved for acquired methemoglobinemia in pediatric and adult patients. Cognitive enhancement, anti-aging, and consumer oral preparations are not covered by that indication.

Approved uses covered here

  • ProvayBlue: acquired methemoglobinemia in pediatric and adult patients

Approved for acquired methemoglobinemia

ProvayBlue is FDA approved for acquired methemoglobinemia in pediatric and adult patients. Cognitive enhancement, anti-aging, and consumer oral preparations are not covered by that indication.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

  • Durable cognitive or functional benefit
  • Safety of repeated wellness exposure
  • Whether research preparations resemble products encountered online

The takeaway

Methylene blue is a medically active drug with a narrow approved use; its interactions matter more than confident online nootropic claims suggest.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. 1
    nihDailyMed: ProvayBlue prescribing information

    Current official label, approved indication, boxed warning, contraindications, and adverse reactions.

  2. 2
    pubmedMethylene blue, functional imaging, and memory

    26-person randomized experiment; short-term task and imaging outcomes.

  3. 3
    pubmedMethylene blue and fear-extinction learning

    42-person claustrophobia experiment; outcomes depended on successful versus unsuccessful exposure learning.

How we assess sources · Suggest a correction